Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy
NCT ID: NCT01673282
Last Updated: 2016-11-15
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
315 participants
OBSERVATIONAL
2012-07-31
2015-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vimpat + Na Channel Blocking AED
Patients prescribed adjunctive lacosamide (LCM) added to one or more baseline Anti-Epileptic Drugs (AEDs) to include at least 1 sodium channel blocking AED.
Lacosamide
Route of Administration: oral/subcutaneous Form and Dosage: Tablet (50 mg/100 mg/150 mg, 200 mg); Syrup (10 mg/ml); Solution for infusion (10 mg/ml).
Vimpat + Non-Na Channel Blocking AED
Patients prescribed adjunctive lacosamide (LCM) added to one or more baseline Anti-Epileptic Drugs (AEDs), none of which is a sodium channel blocking AED.
Lacosamide
Route of Administration: oral/subcutaneous Form and Dosage: Tablet (50 mg/100 mg/150 mg, 200 mg); Syrup (10 mg/ml); Solution for infusion (10 mg/ml).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lacosamide
Route of Administration: oral/subcutaneous Form and Dosage: Tablet (50 mg/100 mg/150 mg, 200 mg); Syrup (10 mg/ml); Solution for infusion (10 mg/ml).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient must have a diagnosis of epilepsy with partial-onset seizures with or without secondary generalization
* Based on the physician's clinical judgment, it is in the patient's best interest to be prescribed adjunctive Vimpat® (ie, the decision to prescribe Vimpat® is made by the physician)
* Patient must be at least 18 years of age
* The patient must have had at least one seizure within the last 3 months prior to enrolment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Clinical Trial Call Center
Role: STUDY_DIRECTOR
UCB Pharma
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
60
Innsbruck, , Austria
61
Mauer bei Amstetten, , Austria
63
Ried, , Austria
18
Berlin, , Germany
34
Berlin, , Germany
43
Berlin, , Germany
66
Berlin, , Germany
23
Bonn, , Germany
28
Cologne, , Germany
40
Cologne, , Germany
25
Dortmund, , Germany
35
Düsseldorf, , Germany
48
Erbach im Odenwald, , Germany
59
Erlangen, , Germany
30
Essen, , Germany
47
Giessen, , Germany
29
Göttingen, , Germany
37
Göttingen, , Germany
05
Haag, , Germany
12
Halle, , Germany
19
Halle, , Germany
39
Heidenheim, , Germany
54
Ibbenbueren, , Germany
27
Jena, , Germany
04
Jülich, , Germany
13
Kehl-Kork, , Germany
36
Kiel, , Germany
38
Leipzig, , Germany
52
Magdeburg, , Germany
67
Mainz, , Germany
49
Mittweida, , Germany
01
München, , Germany
08
Oranienburg, , Germany
17
Osnabrück, , Germany
14
Radeberg, , Germany
15
Rüsselsheim am Main, , Germany
16
Senftenberg, , Germany
41
Stuttgart, , Germany
09
Troisdorf, , Germany
22
Tübingen, , Germany
20
Ulm, , Germany
07
Westerstede, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SP1065
Identifier Type: -
Identifier Source: org_study_id